Skip to main content

The independent medical news service

16-08-2019 | Oncology | Main feed | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

02-08-2019 | Oncology | News | Article

LIPI score associated with survival in metastatic NSCLC irrespective of treatment

An exploratory pooled analysis indicates that the Lung Immune Prognostic Index score is associated with overall survival and progression-free survival in metastatic non-small-cell lung cancer patients receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy.

29-07-2019 | Oncology | News | Article

Hurricane disruption quantified for lung cancer radiotherapy

Hurricane disasters significantly and adversely impact the overall survival of patients undergoing definitive radiotherapy for locally advanced non-small-cell lung cancer, study findings suggest.

22-07-2019 | Oncology | News | Article

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

12-07-2019 | Oncology | News | Article

Low-dose CT provides superior screening for lung cancer death in high-risk smokers

Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.

09-07-2019 | Oncology | News | Article

Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

Image Credits